col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Wiley: British Journal of Clinical Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―23 Science fiction has become reality: best practice for future viral pandemics Daniel F. B. Wright, Carl M. J. Kirkpatrick
2 [GO] 2021―Jul―17 Traditional medicines for COVID-19: Perspectives from clinical pharmacologists Getnet Yimer, Edmund Ekuadzi, Pius Fasinu, Andreia Cristina Melo, Goonaseelan (Colin) Pillai
3 [GO] 2021―Jun―26 Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels Pinar Bakir Ekinci, Emre Kara, Ahmet Gorkem Er, Ahmet Cagkan Inkaya, Kutay Demirkan, Omrum Uzun
4 [GO] 2021―Jun―08 Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed
5 [GO] 2021―May―15 Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia Silvia Corcione, Amedeo De Nicolò, Giorgia Montrucchio, Silvia Scabini, Valeria Avataneo, Chiara Bonetto, et al. (+8)
6 [GO] 2021―May―13 Interferon-α-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 Jiong Yu, Xuan Lu, Ling Tong, Xiaowei Shi, Jing Ma, Feifei Lv, et al. (+5)
7 [GO] 2021―Apr―28 Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom Emma Rezel-Potts, Abdel Douiri, Phil J. Chowienczyk, Martin C. Gulliford
8 [GO] 2021―Apr―26 Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study Janneke P. Spiegelenberg, Marleen M. H. J. Gelder, Martje L. Maas, Marcel M. C. Hovens, Anne Esselink, Anton S. M. Dofferhoff, et al. (+11)
9 [GO] 2021―Apr―23 Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on Clinical Trials and the COVID-19 pandemic Silvia Tusino, Maria Furfaro
10 [GO] 2021―Apr―23 Ethics of vaccination: should capability measures be used to inform SARS-CoV-2 vaccination strategies ? Michael R. Millar, Yannis Gourtsoyannis, Angelina Jayakumar
11 [GO] 2021―Apr―15 Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios Yawen Jiang, Dan Cai, Daqin Chen, Shan Jiang, Lei Si, Jing Wu
13 [GO] 2021―Apr―13 SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? Marko Boskovic, William Migo, Robert Likic
14 [GO] 2021―Mar―25 Liver and kidney function in patients with Covid-19 treated with remdesivir Sylvia A. Laar, Mark G. J. Boer, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling
15 [GO] 2021―Mar―24 Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults? Rafael Dal-Ré
16 [GO] 2021―Mar―20 Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities Vidyasagar Chinni, Hanna El-Khoury, Marlon Perera, Rinaldo Bellomo, Daryl Jones, Damien Bolton, et al. (+2)
17 [GO] 2021―Mar―09 Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A “two-edged sword” hypothesis Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Kalliopi Kotsa
18 [GO] 2021―Feb―20 Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, Jesús M. Alvarado, et al. (+9)
19 [GO] 2021―Feb―20 Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action Lakshmikirupa Sunderesan, Suvendu Giri, Himanshi Singh, Suvro Chatterjee
20 [GO] 2021―Feb―13 Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing? Robert Marcec, Robert Likic
21 [GO] 2021―Jan―28 No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study Roos S.G. Sablerolles, Freija E.F. Hogenhuis, Melvin Lafeber, Bob P.A. Loo, Sander D. Borgsteede, Eric Boersma, et al. (+2)
22 [GO] 2020―Dec―30 INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of randomised studies Frank M.P. Haren, Alice Richardson, Hwan-Jin Yoon, Antonio Artigas, John G. Laffey, Barry Dixon, et al. (+23)
23 [GO] 2020―Dec―30 Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2 Kashyap Patel, Michael Dodds, Antonio Gonçalves, Mohamed A. Kamal, Craig R. Rayner, Carl M. Kirkpatrick, Patrick F. Smith
24 [GO] 2020―Dec―18 A possible increased risk of metamizole-associated neutropenia among COVID-19 patients Tsahi T. Lerman, Moshe Sagi, Yair Shafir, Liron Sheena, Eytan Cohen, Elad Goldberg, Ilan Krause
25 [GO] 2020―Dec―02 Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future Ester Calvo Fernández, Lucie Y. Zhu
26 [GO] 2020―Nov―27 Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review Juan Pimentel, Cassandra Laurie, Anne Cockcroft, Neil Andersson
27 [GO] 2020―Nov―24 Pharmacokinetics under the COVID-19 Storm Venkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, Natalie Giovino, Emily Lythgoe, Shringi Sharma, et al. (+3)
28 [GO] 2020―Nov―21 Chasing COVID-19 chemotherapeutics without putting the cart before the horse Steven P. Rannard, Tom O. McDonald, Andrew Owen
29 [GO] 2020―Nov―21 Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Kraemer, Berthold Hocher
30 [GO] 2020―Nov―13 Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello, Fabrizio Maggi, et al. (+2)
31 [GO] 2020―Oct―30 Risk Assessment of therapeutic agents under consideration to treat COVID-19 in Pediatric Patients and Pregnant Women Jeffrey S. Barrett
32 [GO] 2020―Oct―29 Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs Jun Shi, Yubo Xiao, Yiting Zhang, Donghao Geng, Danhua Cong, Kevin X. Shi, Richard J. Knapp
33 [GO] 2020―Oct―24 Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population - a Danish cohort study Bente Mertz Nørgård, Jan Nielsen, Torben Knudsen, Rasmus Gaardskær Nielsen, Michael Due Larsen, Line Riis Jølving, Jens Kjeldsen
34 [GO] 2020―Oct―21 Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis Rajith K.R. Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, et al. (+17)
35 [GO] 2020―Oct―14 COVID-19 vaccines: the importance of transparency and fact-based education Adam F. Cohen, Joop Gerven, Juan Garcia Burgos, Anthonius Boer, Ron A. M. Foucher, H. Flore, et al. (+4)
36 [GO] 2020―Oct―13 Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic Daniela R. Junqueira, Brian H. Rowe
38 [GO] 2020―Sep―03 Beyond Dexamethasone, Emerging Immuno-Thrombotic Therapies for COVID-19 Melanie Peta Jensen, Marc George, Derek Gilroy, Reecha Sofat
39 [GO] 2020―Aug―31 Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team Karin B. Mirzaev, Yury Kiselev, Dmitriy V. Ivashchenko, Vitaly Otdelenov, Dmitry A. Sychev
40 [GO] 2020―Aug―25 Lessons for teaching from the pandemic Jan Strojil, Hana Suchánková
41 [GO] 2020―Aug―21 Prescribing in COVID-19 patients: Should we take into account inflammation? Catia Marzolini, Manuel Battegay, Parham Sendi, David J. Back
42 [GO] 2020―Aug―17 The COVID-19 Ibuprofen controversy; a systematic review of NSAIDs in adult acute lower respiratory tract infections Ricky Vaja, Jeffery Chan, Plinio Ferreira, Amer Harky, Luke J. Rogers, Hime H. Gashaw, et al. (+2)
43 [GO] 2020―Jul―21 ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19 Benjamin Batteux, Sandra Bodeau, Valérie Gras-Champel, Sophie Liabeuf, Jean-Philippe Lanoix, Jean-Luc Schmit, et al. (+6)
44 [GO] 2020―Jul―21 Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19 Michael G. Dodds, Rajesh Krishna, Antonio Goncalves, Craig R. Rayner
45 [GO] 2020―Jul―18 Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19 Ricardo Peña-Silva, Stephen B. Duffull, Andrew C. Steer, Sandra X. Jaramillo-Rincon, Amanda Gwee, Xiao Zhu
46 [GO] 2020―Jul―15 The impact of the global COVID-19 pandemic on the conduct of clinical trials. Return to normalcy by considering the practical impact of a structured ethical analysis Maurits F.J.M. Vissers, Adam F. Cohen, Joop M.A. Gerven, Geert Jan Groeneveld
47 [GO] 2020―Jul―13 Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials Emma H. Baker, Kamal Patel, Jonathan Ball, Sarah Edwards, Thomas S. Harrison, Arvind Kaul, et al. (+5)
48 [GO] 2020―Jul―08 Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19 Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi
49 [GO] 2020―Jul―06 Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Vedrana Bulat, Mirna Situm, Marija Delas Azdajic, Robert Likic
50 [GO] 2020―Jun―19 Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps Pauline Thémans, Nicolas Dauby, Loïc Schrooyen, Faustine Lebout, Marc Delforge, Rakan Nasreddine, et al. (+9)
51 [GO] 2020―Jun―19 How to expedite early phase SARS-CoV-2 vaccine trials in pandemic setting - a practical perspective J.L. Plas, M. Roestenberg, A.F. Cohen, I.M.C. Kamerling
52 [GO] 2020―Jun―09 A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments Emma H. Baker, Danijela Gnjidic, Carl M.J. Kirkpatrick, Munir Pirmohamed, Daniel F.B. Wright, Anna Y. Zecharia
53 [GO] 2020―May―08 Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic Ahmet Emre Eşkazan
54 [GO] 2020―May―08 COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions David Back, Catia Marzolini, Catherine Hodge, Fiona Marra, Alison Boyle, Sara Gibbons, et al. (+2)
55 [GO] 2020―May―02 Off-target ACE2 ligands: possible therapeutic option for CoVid-19? Simone Brogi, Vincenzo Calderone
56 [GO] 2020―Apr―30 COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients? Hervé Javelot, Wissam El-Hage, Guillaume Meyer, Guillaume Becker, Bruno Michel, Coraline Hingray
57 [GO] 2020―Apr―18 Dosing will be a key success factor in repurposing antivirals for COVID-19 Patrick F. Smith, Michael Dodds, Darren Bentley, Karen Yeo, Craig Rayner


Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.005 sec